CSL’s massive profit increase as vaccines, new products star
Australia’s largest company by market capitalisation, biotechnology manufacturer CSL has powered ahead in the first half of the financial year reporting a net profit after tax up 44 per cent on the previous corresponding period. The company, which is in the final stages of manufacturing the AstraZeneca Covid-19 vaccine, reported a NPAT of $1.8 billion…